title: Ustekinumab in Crohn's disease: evidence to date and place in therapy.
abstract: Crohn's disease (CD) is an inflammatory bowel disease (IBD) with uncertain etiology. Biologic agents have revolutionized the treatment of CD but nonresponders remain a challenge. Ustekinumab is an interleukin 12/23p40 inhibitor that was recently found effective in treating CD. We reviewed the current literature regarding the efficacy of ustekinumab in treating CD and concluded that ustekinumab is a novel, promising and relatively safe agent for the treatment of moderate to severe CD. Additional data from randomized controlled studies and real-life cohorts are pending.
authors.affiliation: Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel Hashomer, Israel.
authors.forename: Tal
authors.initials: T
authors.lastname: Engel
authors.affiliation: Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel Hashomer, 52621, Israel.
authors.forename: Uri
authors.initials: U
authors.lastname: Kopylov
keywords: Crohn’s disease; interleukin 12/23p40 inhibitor; ustekinumab